Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03943901 Recruiting - Cancer Clinical Trials

Split-Dose R-CHOP for Older Adults With DLBCL

Start date: February 17, 2021
Phase: Phase 2
Study type: Interventional

This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).

NCT ID: NCT03942263 Completed - Hodgkin Disease Clinical Trials

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

KLIO
Start date: May 31, 2019
Phase:
Study type: Observational

The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.

NCT ID: NCT03939182 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Start date: May 29, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.

NCT ID: NCT03939026 Active, not recruiting - Clinical trials for Relapsed/Refractory Follicular Lymphoma

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

ALPHA
Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

NCT ID: NCT03938987 Recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

ACIT001/EXC002
Start date: March 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

NCT ID: NCT03936465 Active, not recruiting - Lymphoma Clinical Trials

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Start date: September 27, 2019
Phase: Phase 1
Study type: Interventional

Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain tumors or pediatric tumors that have spread to the brain.

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.

NCT ID: NCT03936153 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

NCT ID: NCT03934814 Completed - Lymphoma Clinical Trials

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Start date: April 16, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

NCT ID: NCT03934567 Recruiting - Clinical trials for Lymphoma, Follicular

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: April 22, 2020
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)